← Back to Search

Tyrosine Kinase Inhibitor

Targeted Cancer Drugs for Cancer (CAPTUR Trial)

Phase 2
Recruiting
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status 0-2
Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment known to prolong life, or who has refused such treatment
Must not have
Patients with known left ventricular ejection fraction (LVEF) < 40%
Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the effects of targeted cancer drugs on patients with specific gene changes.

Who is the study for?
Adults with incurable metastatic solid tumors, multiple myeloma, or B cell non-Hodgkin lymphoma without standard life-prolonging treatment options. Participants must be over 18, have an ECOG performance status of 0-2, normal organ function and measurable disease. They should agree to use effective contraception and not have other conditions that could affect the trial's safety or results.
What is being tested?
The CAPTUR study is testing targeted therapy drugs on patients with specific abnormal gene changes in their cancer. These therapies aim at the genetic level to block cancer growth and spread. The trial includes a variety of drugs like Erlotinib and Nivolumab plus Ipilimumab among others.
What are the potential side effects?
Potential side effects depend on the drug given but may include fatigue, skin reactions, digestive issues, blood count changes, liver function alterations and increased risk of infections. Some drugs might also cause heart problems or interfere with wound healing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and am up and about more than half of the day.
Select...
I am an adult with an incurable cancer (not brain cancer) and no life-prolonging treatment options or have refused them.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My heart's pumping ability is below 40%.
Select...
I do not have serious heart conditions like uncontrolled chest pain or heart failure.
Select...
I have had a serious stomach or intestinal bleed in the last month.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Objective response rate defined as the number of patients with complete response or partial response
Secondary study objectives
Number and severity of adverse events grade >3, or of lesser grade resulting in discontinuation, delay or reduction in dose of study drug

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

14Treatment groups
Experimental Treatment
Group I: Group 9 Arm CLOSEDExperimental Treatment1 Intervention
CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
Group II: Group 8 - Arm CLOSEDExperimental Treatment1 Intervention
CDKN2A, CDK4, CCND1, SMARCA4
Group III: Group 7 - Arm CLOSEDExperimental Treatment1 Intervention
BRCA1, BRCA2, mutations in HRD
Group IV: Group 6 - Arm CLOSEDExperimental Treatment1 Intervention
high mutation burden, POLE, POLD1
Group V: Group 5 - Arm CLOSEDExperimental Treatment1 Intervention
EGFR
Group VI: Group 4 - Arm CLOSED, no patients recruitedExperimental Treatment1 Intervention
KIT, PDGFRA, PDGFRB, ABL1
Group VII: Group 3 - Arm CLOSEDExperimental Treatment1 Intervention
ALK, ROS1, MET
Group VIII: Group 2 - Arm CLOSED, no patients recruitedExperimental Treatment1 Intervention
BCR-ABL, SRC
Group IX: Group 14Experimental Treatment1 Intervention
ERBB2
Group X: Group 13 - Arm CLOSEDExperimental Treatment1 Intervention
PTCH1, SMO
Group XI: Group 12 - Arm CLOSEDExperimental Treatment1 Intervention
BRAFV600
Group XII: Group 11 - Arm CLOSEDExperimental Treatment1 Intervention
ERBB2
Group XIII: Group 10 Arm CLOSEDExperimental Treatment1 Intervention
AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
Group XIV: Group 1 - Arm CLOSED, no patients recruitedExperimental Treatment1 Intervention
VEGFR1, VEGFR2, VEGFR3
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sunitinib
2014
Completed Phase 3
~4380
Olaparib
2007
Completed Phase 4
~2190
Tucatinib
2017
Completed Phase 2
~520
Dasatinib
2012
Completed Phase 3
~2320
Axitinib
2020
Completed Phase 2
~3050
Palbociclib
2017
Completed Phase 3
~3790
Erlotinib
2011
Completed Phase 4
~2290
Nivolumab plus Ipilimumab
2015
Completed Phase 2
~90
Vismodegib
2015
Completed Phase 4
~1880
Bosutinib
2015
Completed Phase 3
~3040
Crizotinib
2014
Completed Phase 3
~2960
Temsirolimus
2008
Completed Phase 2
~1940

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheIndustry Sponsor
2,457 Previous Clinical Trials
1,097,012 Total Patients Enrolled
13 Trials studying Multiple Myeloma
1,765 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbIndustry Sponsor
2,688 Previous Clinical Trials
4,096,388 Total Patients Enrolled
91 Trials studying Multiple Myeloma
21,694 Patients Enrolled for Multiple Myeloma
PfizerIndustry Sponsor
4,661 Previous Clinical Trials
17,844,205 Total Patients Enrolled
41 Trials studying Multiple Myeloma
9,939 Patients Enrolled for Multiple Myeloma

Media Library

Axitinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03297606 — Phase 2
Multiple Myeloma Research Study Groups: Group 3 - Arm CLOSED, Group 1 - Arm CLOSED, no patients recruited, Group 2 - Arm CLOSED, no patients recruited, Group 9 Arm CLOSED, Group 8 - Arm CLOSED, Group 13 - Arm CLOSED, Group 7 - Arm CLOSED, Group 5 - Arm CLOSED, Group 12 - Arm CLOSED, Group 4 - Arm CLOSED, no patients recruited, Group 10 Arm CLOSED, Group 11 - Arm CLOSED, Group 6 - Arm CLOSED, Group 14
Multiple Myeloma Clinical Trial 2023: Axitinib Highlights & Side Effects. Trial Name: NCT03297606 — Phase 2
Axitinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03297606 — Phase 2
~107 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top